To observe the effecta of Shenyi capsule combined with gefitinib on serum MMP-9 in patients with advanced non-small cell lung cancer.Methods:A total of 126 NSCLC patients admitted to our hospital from March 2015 to January 2017 were randomly divided into observation group (Shenyi capsule+gefitinib) and control group (gefitinib Nigeria).After 60 days of treatment, the clinical efficacy of the two groups were compared, and the changes of serum MMP-9 and TIMP-1, the quality of life (QOL) before and after treatment were compared.Based on the WHO classification of common toxicity of chemotherapy drugs, the occurrence of patients and drug-related serious adverse reactions (III, IV) were recorded.Results:The total remission rate was 63.93% in the observation group and 55.74% in the control group.There was no significant difference between the two groups (P>0.05).After treatment, the expression of MMP-9 in the observation group and the control group decreased significantly, while the expression of MMP-9 in the observation group was lower than that in the control group (P<0.05).There was no significant change in the expression of TIMP-1 in the observation group, but TIMP-1 expression was increased in the control group (P<0.05).After treatment, the QOL scores decreased in both groups, with significant difference (P<0.05).The QOL score in observation group decreased more than that in control group (P<0.05).The incidence of adverse reactions in the observation group was 9.84% and in the control group was 24.59%.The incidence of adverse reactions in the observation group was lower than that in the control group (P<0.05).Conclusion:Adding Shenyi Capsule to gefitinib in patients with advanced non-small cell lung cancer can reduce adverse reactions caused by chemotherapeutic drugs, improve patients' quality of life and reduce the serum MMP-9 expression, which can help to delay the invasion and metastasis of tumor cells.